| New Castle Health And Rehabilitation Center | |
| 32 Buena Vista Drive, New Castle, Delaware 19720 | |
| (302) 328-2580 | |
| Name | New Castle Health And Rehabilitation Center |
|---|---|
| Location | 32 Buena Vista Drive, New Castle, Delaware |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 120 |
| Occupancy Rate | 88.75% |
| Medicare ID (CCN) | 085039 |
| Legal Business Name | New Castle Health & Rehabilitation Center Llc |
| Ownership Type | For Profit - Partnership |
| NPI Number | 1013306919 |
| Organization Name | OAK HRC NEW CASTLE LLC |
| Doing Business As | NEW CASTLE HEALTH AND REHABILITATION CENTER |
| Address | 32 Buena Vista Dr, New Castle, DE 19720 |
| Phone Number | 302-328-2580 |
News Archive
People who take the newest class of diabetes drugs to control blood sugar are twice as likely as those on other forms of sugar-control medication to be hospitalized with pancreatitis, Johns Hopkins researchers report.
Scientists have made it easier to predict both breast cancer relapses and responses to chemotherapy, through the identification of a unique gene. The newly found marker could help doctors classify each breast cancer patient and customise a treatment regimen that is more effective.
Patrys Limited, a clinical stage biotechnology company, is pleased to announce the clinical results from a patient treated with PAT-SM6 in combination with other marketed multiple myeloma drugs.
For the first time, Brazil in 2013 will enter into a new type of public-private partnership that allows the nation to produce a generic version of the antiretroviral (ARV) drug atazanavir sulphate, which will be under patent through its producer Bristol-Myers Squibb until 2017, Inter Press Service reports.
Polyphor today presented promising data for their novel class of antibiotics, the Outer Membrane Protein Targeting Antibiotics (OMPTA). This is the first new class of antibiotic against Gram-negative pathogens to reach advanced clinical development in over 40 years.
› Verified 6 days ago
| NPI Number | 1114090503 |
| Organization Name | NEW CASTLE CARE, LLC |
| Doing Business As | ARBORS AT NEW CASTLE SUBACUTE & REHAB CENTER |
| Address | 32 Buena Vista Dr, New Castle, DE 19720 |
| Phone Number | 302-328-2580 |
News Archive
People who take the newest class of diabetes drugs to control blood sugar are twice as likely as those on other forms of sugar-control medication to be hospitalized with pancreatitis, Johns Hopkins researchers report.
Scientists have made it easier to predict both breast cancer relapses and responses to chemotherapy, through the identification of a unique gene. The newly found marker could help doctors classify each breast cancer patient and customise a treatment regimen that is more effective.
Patrys Limited, a clinical stage biotechnology company, is pleased to announce the clinical results from a patient treated with PAT-SM6 in combination with other marketed multiple myeloma drugs.
For the first time, Brazil in 2013 will enter into a new type of public-private partnership that allows the nation to produce a generic version of the antiretroviral (ARV) drug atazanavir sulphate, which will be under patent through its producer Bristol-Myers Squibb until 2017, Inter Press Service reports.
Polyphor today presented promising data for their novel class of antibiotics, the Outer Membrane Protein Targeting Antibiotics (OMPTA). This is the first new class of antibiotic against Gram-negative pathogens to reach advanced clinical development in over 40 years.
› Verified 6 days ago
| NPI Number | 1962994905 |
| Organization Name | NEW CASTLE HEALTH & REHABILITATION CENTER, LLC |
| Address | 32 Buena Vista Dr, New Castle, DE 19720 |
| Phone Number | 302-328-2580 |
News Archive
People who take the newest class of diabetes drugs to control blood sugar are twice as likely as those on other forms of sugar-control medication to be hospitalized with pancreatitis, Johns Hopkins researchers report.
Scientists have made it easier to predict both breast cancer relapses and responses to chemotherapy, through the identification of a unique gene. The newly found marker could help doctors classify each breast cancer patient and customise a treatment regimen that is more effective.
Patrys Limited, a clinical stage biotechnology company, is pleased to announce the clinical results from a patient treated with PAT-SM6 in combination with other marketed multiple myeloma drugs.
For the first time, Brazil in 2013 will enter into a new type of public-private partnership that allows the nation to produce a generic version of the antiretroviral (ARV) drug atazanavir sulphate, which will be under patent through its producer Bristol-Myers Squibb until 2017, Inter Press Service reports.
Polyphor today presented promising data for their novel class of antibiotics, the Outer Membrane Protein Targeting Antibiotics (OMPTA). This is the first new class of antibiotic against Gram-negative pathogens to reach advanced clinical development in over 40 years.
› Verified 6 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
People who take the newest class of diabetes drugs to control blood sugar are twice as likely as those on other forms of sugar-control medication to be hospitalized with pancreatitis, Johns Hopkins researchers report.
Scientists have made it easier to predict both breast cancer relapses and responses to chemotherapy, through the identification of a unique gene. The newly found marker could help doctors classify each breast cancer patient and customise a treatment regimen that is more effective.
Patrys Limited, a clinical stage biotechnology company, is pleased to announce the clinical results from a patient treated with PAT-SM6 in combination with other marketed multiple myeloma drugs.
For the first time, Brazil in 2013 will enter into a new type of public-private partnership that allows the nation to produce a generic version of the antiretroviral (ARV) drug atazanavir sulphate, which will be under patent through its producer Bristol-Myers Squibb until 2017, Inter Press Service reports.
Polyphor today presented promising data for their novel class of antibiotics, the Outer Membrane Protein Targeting Antibiotics (OMPTA). This is the first new class of antibiotic against Gram-negative pathogens to reach advanced clinical development in over 40 years.
› Verified 6 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 3 |
| Total Amount of Fines in Dollars | $82876 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 3 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 21.29 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 10.39 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 41.6 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.28 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 2.68 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 2.27 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 1.53 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 95.91 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 10.59 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 86.08 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 4.03 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 34.35 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 24.33 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 7.17 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 97.17 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 59.89 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 79.78 | 82.93 |
News Archive
People who take the newest class of diabetes drugs to control blood sugar are twice as likely as those on other forms of sugar-control medication to be hospitalized with pancreatitis, Johns Hopkins researchers report.
Scientists have made it easier to predict both breast cancer relapses and responses to chemotherapy, through the identification of a unique gene. The newly found marker could help doctors classify each breast cancer patient and customise a treatment regimen that is more effective.
Patrys Limited, a clinical stage biotechnology company, is pleased to announce the clinical results from a patient treated with PAT-SM6 in combination with other marketed multiple myeloma drugs.
For the first time, Brazil in 2013 will enter into a new type of public-private partnership that allows the nation to produce a generic version of the antiretroviral (ARV) drug atazanavir sulphate, which will be under patent through its producer Bristol-Myers Squibb until 2017, Inter Press Service reports.
Polyphor today presented promising data for their novel class of antibiotics, the Outer Membrane Protein Targeting Antibiotics (OMPTA). This is the first new class of antibiotic against Gram-negative pathogens to reach advanced clinical development in over 40 years.
› Verified 6 days ago
New Castle Health And Rehabilitation Center Location: 32 Buena Vista Drive, New Castle, Delaware 19720 Phone: (302) 328-2580 |